Casp8 acts through A20 to inhibit PD‐L1 expression: The mechanism and its implication in immunotherapy

Immunotherapy targeting the PD‐L1/PD‐1 pathway is a novel type of clinical cancer treatment, but only small subsets of patients can benefit from it because of multiple factors. PD‐L1/PD‐1 expression is a biomarker for predicting the efficacy of anti‐PD‐L1/PD‐1 therapy, which highlights the importanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Jiahuan, Xia, Hongwei, Zhang, Chenliang, Xu, Huanji, Tang, Qiulin, Zhu, Gongmin, Li, Jielang, Bi, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253292/
https://www.ncbi.nlm.nih.gov/pubmed/33934451
http://dx.doi.org/10.1111/cas.14932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253292/
https://www.ncbi.nlm.nih.gov/pubmed/33934451
http://dx.doi.org/10.1111/cas.14932

Ejemplares similares